Mydecine

Mydecine Innovations Group, or simply Mydecine, is an American and Canadian pharmaceutical company that is developing psychedelics and entactogens as medicines.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Mydecine Innovations Group, or simply Mydecine, is an American and Canadian pharmaceutical company that is developing psychedelics and entactogens as medicines. In August 2022, it was reported that Mydecine was experiencing financial difficulties and might cease operations. However, the company was able to obtain more funding and did not shutdown.

Mydecine made the first legal import of magic mushrooms into Canada in 2021. Mydecine's drug candidates include the psychedelics psilocybin (MYCO-001, MYCO-003), MYCO-004 (a patch-delivered tryptamine), and MYCO-005 (a novel aza psilocin analogue with putatively better safety) and the novel MDMA-like entactogens MYCO-002 (putatively safer), MYCO-006 (short-acting), and MYCO-007 (short-acting).

Although the chemical structures of most of its drug candidates have not been disclosed, Mydecine has patented (MY100) and (MY101) as short-acting MDMA analogues.

See also

List of psychedelic pharmaceutical companies List of investigational hallucinogens and entactogens

Mydecine Website (Archived) Mydecine - LinkedIn Mydecine - Google Patents

Text derived from https://en.wikipedia.org/w/index.php?oldid=1378834743 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

23 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.